NEWS

September 1st, 2021

Stellate Therapeutics Publishes Positive Results in PLOS ONE on Neuroprotective Properties of Lead Candidate STL-101

Read more

June 17th, 2021

Stellate Therapeutics Strengthens Senior Management Team 

Read more

May 18th, 2021

Stellate Therapeutics Appoints Sophie Durand as Chief Executive Officer and Announces Capital Raise

Read more
Stellate Therapeutics Publishes Positive Results in PLOS ONE on Neuroprotective Properties of Lead Candidate STL-101

Press Release

September 1st, 2021
Read more
Stellate Therapeutics Strengthens Senior Management Team

Press Release

June 17th, 2021
Read more
Stellate Therapeutics Appoints Sophie Durand as Chief Executive Officer and Announces Capital Raise

Press Release

May 18th, 2021
Read more

© 2022 Stellate Therapeutics. All Rights Reserved.

France HQ – 47 Rue de Montmorency, 75003 Paris Stellate Inc. – 101 Avenue of the Americas, JLABS @ NYC, New York, NY 10013

© 2022 Stellate Therapeutics. All Rights Reserved.